A recent study presented at EULAR found that a substantial number of patients who switched treatment from reference etanercept to a biosimilar switched back to the reference after a short period.
A recent study, sponsored by Pfizer and presented in a European League Against Rheumatism (EULAR) poster session earlier this month, found that a substantial number of patients who had switched treatment from reference etanercept to a biosimilar treatment switched back to the reference product after a short time.
The study’s authors sought to describe the position of the reference etanercept treatment within the Swedish biologics market for rheumatic diseases, including rheumatoid arthritis, before and after the launch of a biosimilar product.
The market share for each product was tracked using prescription data from the Swedish Prescription Registry (which covers 100% of prescriptions written in Sweden) for each month during the period between November 2015 and October 2016. The researchers tracked the switching dynamics of patients initiating the biosimilar treatment between April 2016 and October 2016, and measured the proportion of patients naïve to biologic treatment as well as the proportion of patients who had been treated with etanercept, adalimumab, and other biologic agents in the 12 months prior to initiating treatment with biosimilar etanercept.
The researchers found that, in the first 6 months after biosimilar etanercept was launched in the Swedish market, the market share of reference etanercept decreased from 40% to 31%. A total of 2439 patients were found to have initiated treatment with biosimilar etanercept, and of this group, 40.1% were naïve to biologic treatments, 48.3% had previously been treated with reference etanercept, 4.4% had been previously treated with adalimumab, and 7.2% had been previously treated with other biologics.
Among the group of patients who initiated biosimilar etanercept after having previously received its reference, 7% switched back to the reference after an average period of 43 days. Of the group who had previously received adalimumab, 6% switched back to treatment with adalimumab after an average of 57 days.
The researchers concluded that a switch from reference products to cheaper biosimilars is very likely to be a result of economic factors, however, the reasons for patients’ switching back to reference products is not clear. The researchers posit patient preference and clinical factors as possible reasons for such a return, but they state that longer-term studies will be necessary in order to confirm these preliminary findings.
The results of this study echo those of a previous study, also funded by Pfizer and conducted in Germany by the same research group, which found that 10% of patients who switched to biosimilar etanercept returned to treatment with its reference within 3 months. In the German study, 72% of patients who switched back to reference products returned to the same administration method they had used previously, suggesting that device type may have played a role.
As health systems contend with high prescription drug costs and patients find themselves with questions and concerns about switching, other European nations are turning to education programs to help keep patients on lower-cost biosimilars, though it remains to be seen whether such programs can prevent patients from switching back to reference products in the longer term.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More
May 13th 2024A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.